Monisha Singh, MD

Instructor in Medicine, Academic Institute
Department of Medicine
Cancer Center
Houston Methodist Hospital
Houston Methodist
Weill Cornell Medical College

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Education/Academic qualification

Hematology/Oncology, Clinical Fellowship, LAC-Olive View/UCLA Medical Center

Jul 1 2004 → Jun 30 2007

Award Date: Jun 30 2007

Internal Medicine, Residency, LAC-Harbor-UCLA Medical Center

Jun 1 2002 → Jun 30 2004

Award Date: Jun 30 2004

Internal Medicine, Internship, LAC-Harbor-UCLA Medical Center

Jun 1 2001 → Jun 30 2002

Award Date: Jun 30 2002

MD, University of California at Los Angeles School of Medicine

Jul 1 1997 → Jun 30 2001

Award Date: Jun 30 2001

Fingerprint

Dive into the research topics where Monisha Singh is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

3 Not started
92 Active

A011502 ABC STUDY CIRB SUBMISSION
Arentz, C., Chang, J. C., Darcourt, J., Heyne, K., Niravath, P. A. & Singh, M.
11/17/20 → …
Project: Clinical Trial
Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (CREST)
Satkunasivam, R., Darcourt, J., Singh, M. & Zhang, J.
8/6/20 → …
Project: Clinical Trial
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
Pingali, S. R., Abdelrahim, M., Bernicker, E. H., Chang, J. C., Darcourt, J., Heyne, K., Niravath, P. A., Petkova, J., Randhawa, J., Rice, L. & Singh, M.
7/8/20 → …
Project: Clinical Trial
An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without Chemotherapy, Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Darcourt, J., Singh, M. & Zhang, J.
7/2/20 → …
Project: Clinical Trial
Phase 3 Multicenter, Double-Blind, randomized, placebo-controlled trail of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302)
Satkunasivam, R., Darcourt, J., Singh, M. & Zhang, J.
6/26/20 → …
Project: Clinical Trial

4 Citations
1 h-Index
1 Article

Successful treatment of a stage IIIC small-cell carcinoma of the ovary hypercalcemic subtype using multi-modality therapeutic approach
Qin, Q., Ajewole, V. B., Sheu, T. G., Donohue, R. & Singh, M., May 3 2018, In : ecancermedicalscience. 12, 832.
Research output: Contribution to journal › Article
4 Scopus citations

Education/Academic qualification

A011502 ABC STUDY CIRB SUBMISSION

Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (CREST)

A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)

An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without Chemotherapy, Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Phase 3 Multicenter, Double-Blind, randomized, placebo-controlled trail of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302)

Successful treatment of a stage IIIC small-cell carcinoma of the ovary hypercalcemic subtype using multi-modality therapeutic approach